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Abstract
Background Tubeimoside I (TBMS1) was isolated from
the tubers of Bolbostemma paniculatum (Maxim.) Fran-
quet. TBMS1 shows potent anti-tumor activity. The present
study was conducted to investigate the anti-microtubule
role of TBMS1 and its binding site of tubulin.
Methods Cell growth inhibition was measured by MTT
after treatment with TBMS1. Uptake kinetics of TBMS1 by
human nasopharyngeal carcinoma CNE-2Z cell line
(CNE-2Z) was assayed by HPLC. Microtubule protein
(MTP) was prepared from porcine brain through two cycles
of polymerization–depolymerization in a high molarity
buffer. Inhibition of MTP polymerization induced by
TBMS1 was determined by a turbidity measurement and a
sedimentation assay; the interactions of TBMS1 with
tubulin within CNE-2Z cells were investigated by immu-
noﬂuorescence microscopy and immunoblotting. TBMS1
was tested for its ability to inhibit binding of known tubulin
ligands through competitive binding assay.
Results TBMS1 displayed growth inhibitory activity
against CNE-2Z cells with IC50 value of 16.7 lM for 72 h.
HPLC analysis of TBMS1 uptake by CNE-2Z cells dis-
played the initial slow TBMS1 uptake and then gradually
reaching an maximum uptake near 18 h. CNE-2Z cells
treated with TBMS1 (25 lM, 3 h) were sufﬁcient to cause
the microtubular network disruption. Immunoblot analysis
showed that the proportion of cytosolic tubulin of cells
treated with TBMS1 increased in a time- and concentra-
tion-dependent manner. TBMS1 did not inhibit the binding
of vinblastine to tubulin. Colchicine binding to tubulin was
inhibited in the presence of TBMS1.
Conclusions TBMS1 is an anti-microtubule agent, and its
binding site of tubulin is the colchicine binding site of
tubulin.
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Introduction
‘‘Tu-Bei-Mu’’, Bolbostemma paniculatum (Maxim.) Fran-
quet (Cucurbitaceae) is a traditional Chinese medicinal
plant, which was listed in the Supplement to the Com-
pendium of Materia Medica, compiled in 1765, at the time
of the Qing Dynasty. Its stem tuber was employed, for
example, in the treatment of breast carcinoma, mammary
abscess, cyclomastopathy and tuberculosis of lymph node,
in ancient times, and was very effective in resolving
masses and reducing swellings [1]. Some physicians of
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provinces used to apply it to treatment of esophagus car-
cinoma and stomach cancer with considerable efﬁciency
during the 70s of last century, but the side-effects, such as
nausea, vomiting, etc., were quite serious. Tubeimoside I
(TBMS1), a bisdesmosidic triterpenoid saponin whose
sugar chains are connected by 3-hydroxyl-3-methylglutaric
acid to form a unique macrocyclic structure, was isolated
from the tubers of Bolbostemma paniculatum (Fig. 1)
[2, 3]. Our previous studies demonstrated that TBMS1 had
potent anti-tumor, anti-tumor-promoting, and anti-meta-
static activities [4–7], and induced cell cycle arrest and
apoptosis in human promyelocytic leukemia (HL-60) [8],
and HeLa cells [9], and nasopharyngeal carcinoma
CNE-2Z cell line (CNE-2Z) [10].
Normal cell division, intracellular transport, cellular
motility, cell signaling, and maintenance of cell shape are
all dependent on highly regulated dynamic instability
process of the tubulin/microtubule system. Microtubules
are hollow tubes consisting of a- and b-tubulin heterodi-
mers that polymerize parallel to a cylindrical axis. Mitotic
microtubules are very dynamic structures, switching
between growing and shortening states, a process known as
dynamic instability and driven primarily by the catastrophe
rate. Microtubule-associated proteins (MAPs) bind to and
stabilize microtubules by reducing the catastrophe rate or
increasing the polymerization rate.
Microtubule poisons like the Vinca alkaloids and
colchicines have been known for decades for their
depolymerizing effects on microtubules. In 1980, the
mechanism of action of the cytotoxic anti-tumor agent
Taxol was discovered [11]. Taxol, unlike other microtu-
bule-interacting agents previously identiﬁed, promotes the
polymerization of tubulin into microtubules. The mecha-
nism of action of paclitaxel has been well documented and
includes the premature polymerization of tubulin resulting
in hyperstable microtubule formation, inhibition of cellular
proliferation at the G2/M phase of the cell cycle, mitotic
spindle disorganization, and cell death. Taxol is clinically
effective anti-cancer agent and represents perhaps the most
signiﬁcant addition to the pharmacopoeia of cancer che-
motherapeutic agents in the last decade [12]. Prompted by
the clinical successes of the taxanes, Taxol
TM (paclitaxel)
and Taxotere
TM (docetaxel), signiﬁcant efforts have been
focused on identifying new agents that have a similar
mechanism of action yet superior properties such as agents
that are poor substrates of Pgp4-mediated transport and
exhibit better solubility in aqueous solutions. The discov-
ery of new natural and semisynthetic compounds being
cytotoxic by interference with tubulin have attracted much
attention within the last years, the microtubule complex has
thus proven to be a compelling target for the development
of anti-cancer therapeutic agents [13, 14].
Our recent studies showed that TBMS1 opens the per-
meability transition pore, thereby decreasing mitochondrial
membrane potential, releasing cytochrome c from mito-
chondria, and further causing a series of events consistent
with established mechanistic models of apoptosis. An
important point to be stressed is that the effects of TBMS1
on mitochondria and mitochondrial cytochrome c were
observed at rather high concentrations of TBMS1
([20 lM) [15]. Therefore, only the effects of TBMS1 on
mitochondria and mitochondrial cytochrome c are not
sufﬁcient to explain the mechanisms of TBMS1-induced
apoptosis in human tumor cells. Since TBMS1 is capable
of inhibiting angiogenesis [16], and certain relationship
exists between anti-angiogenesis and anti-microtubule
effects of drugs [17], it is interesting to study the anti-
microtubule activity of TBMS1 and its binding site of
tubulin.
Materials and methods
Collection of ‘‘Tu-Bei-Mu’’ and preparation of TBMS1
‘‘Tu-Bei-Mu’’ was collected at Shaanxi Province (China),
and identiﬁed by Professor Quan Y (Department of Botany,
Shaanxi Provincial Academy of Traditional Chinese
Medicine and Pharmacy, China). A voucher specimen (No.
097) has been deposited in the Key Laboratory of Marine
Materia Medica, Guangdong Ocean University, Zhanjiang
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Fig. 1 Chemical structural formula of TBMS1
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123524025, China. TBMS1 was isolated from tubers of B.
paniculatum (Maxim.) Franquet (Cucurbitaceae) by the
method reported previously [2, 3]. Its structural formula
was established by Kong et al. [3]. The purity of TBMS1
was [98.5% (estimated by HPLC). The puriﬁed TBMS1
was solubilized in distilled water, and the stock solutions
were stored at -20C with no evidence of chemical
degradation over time.
Chemicals
Paclitaxel, colchicine, Vinblastine, adenosine 50-triphosphate
(ATP), guanosine triphosphate (GTP), ethyleneglycol-
bis(b-aminoethylether)-N,N,N0,N0-tetra acetic acid (EGTA),
and 2-[N-morpholino]ethanesulfonic acid (MES), PIPES and
Triton X-100 were purchased from Sigma Chemical Co.
Mouse monoclonal anti-tubulin antibody was obtained from
NeoMarkers Corp. Nitrocellulose membranes were the
productofPallCorp.Super
1WestPicokitwasobtainedfrom
Pierce Corp. [
3H]vinblastine (8 Ci/mmol) and MicroSpin
TM
G-50 (superﬁne) were purchased from Amersham, and
[
3H]colchicine (70 Ci/mmol) was purchased from DuPont.
RPMI-1640 medium was purchased from HyClone Co.
Newborn calf serum (NCS) was obtained from Sijiqing
Biological Material Co. (Hangzhou, China). All other
chemicals used were of reagent grade.
Cell line and cell culture
The CNE-2Z cell line from a Cantonese patient established
by Gu et al. [18] was obtained from Guangdong Medical
College. Cells were cultured in RPMI-1640 medium sup-
plemented with 10% (v/v) heat-inactivated NCS, 100 U/ml
penicillin, 100 lg/ml streptomycin and 2 g/l NaHCO3 at
37C in humidiﬁed air containing 5% CO2 in monolayer.
Cells in log phase growth were used in the experiments.
MTT assay
The mitochondrial metabolism of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) to its insol-
uble blue formazan was used for enumerating cells to
assess the anti-proliferative effects of TBMS1 according to
the methods of Hansen et al. [19]. Brieﬂy, Single-cell
suspensions were prepared and seeded into 96 well
microculture plates with 1.0 9 10
5 cells/ml (90 ll/well).
Cells were cultured for 12 h before addition of TBMS1.
TBMS1 was diluted into RPMI-1640 medium and added to
each well in a volume of 10 ll. Cells were incubated at
37C for the time indicated. MTT solution (5 mg/ml) was
aliquoted to each well in a volume of 20 ll, and 5 h later
100 ll of the solubilization solution [10% SDS–5% iso-
butyl alcohol–0.012 M HCl (w/v/v)] was added into each
well. The plates were allowed to stand overnight in the
incubator in a humidiﬁed atmosphere. Absorbance at
570 nm (A570) was determined for each well using an
ELISA reader. Control wells contained all of the agents
presented in the treated wells except TBMS1. Each
experimental point was performed in three replicates. The
50% inhibitory concentration (IC50) was determined from
dose-response data from at least three experiments.
Uptake of TBMS1 by CNE-2Z cells
CNE-2Z (5 9 10
5) cells were cultured with a ﬁnal con-
centration of TBMS1 of 30 lMa t3 7 C, pH 7.4. Samples
were taken at speciﬁed time intervals and the supernatant
was seperated by centrifugation for 5 min at room tem-
perature and 7,500g in an Eppendorf 3200 centrifuge. The
CNE-2Z cell fraction was resuspended in about 10 vol. of
cold PBS and seperated by the short centrifugation three
times described above, and the concentrated cells were
resuspended in deionized water and homogenized by son-
ication. The supernatant was obtained by centrifugation at
2,000g for 5 min, and then deproteinized with 10% (W/V)
trichloroacetic acid. The methanolic extracts were used for
the assays of TBMS1 concentrations by HPLC using
Hypersil ODS column (5 lm 4.0 9 250 mm) [20].
MTP preparation and puriﬁcation
Microtubule protein (MTP) was prepared and puriﬁed from
fresh porcine brains through two cycles of polymerization–
depolymerization in a high molarity PIPES buffer. Fresh
brains were obtained from a local abattoir and put into a bag
in ice to be transferred quickly to the laboratory as soon as
the pig was butchered. The blood vessels, meninges and
other impurities were removed after weighing. The prepa-
ration and puriﬁcation of MTP were performed according to
the methods of Castoldi and Popov [21]. The solution of
MTP was stored in liquid nitrogen as 1–2 ml aliquots until
used. The protein content was estimated by Lowry’s method
[22] using bovine serum albumin as a standard.
The composition of MTP, which is composed of tubulin
and MAPs, was investigated by densitometry of a Coo-
massie brilliant blue-stained sodium dodecylsulphate
polyacrylamide gel electrophoresis (SDS-PAGE) gel.
Tubulin identity was conﬁrmed with a commercial anti-
tubulin antibody by immunoblotting.
Eight or sixteen micrograms sample (ﬁnal volume 8 ll)
was mixed with 2 ll59 sample-dissociating buffer and
Cancer Chemother Pharmacol (2008) 62:559–568 561
123boiled for 4 min. These samples were loaded on 10% (w/v)
SDS-polyacrylamide gel and electrophoresis was per-
formed. Proteins were transferred to nitrocellulose
membranes by electroblotting. The membrances were
blocked with 10% (w/v) fat-free milk and incubated with
the monoclonal mouse anti-tubulin antibody (at 1:500
dilution) in 5% (w/v) fat-free milk in TTBS buffer (150 mM
NaCl, 50 mM Tris–HCl, pH 7.5, 0.05% v/v Tween-20) for
2 h at room temperature. The immunoreactive proteins
were probed with horseradish peroxidase-conjugated goat
anti-mouse IgG, protein levels were visualized by peroxi-
dase reaction using Super
1West Pico kit.
Microtubule assembly assay
The microtubule assembly was monitored spectroscopi-
cally by turbidity measurement at 350 nm using a
spectrophotometer (UV-1601, SHIMADZU, Japan) equip-
ped with a thermostatically regulated liquid circulator [23].
The constituents of the assay (freshly thawed MTP, ATP,
MES buffer and test compounds) and cuvettes were kept
cold on ice. Paclitaxel, as a positive control, was dissolved
in dimethyl sulfoxide (DMSO) and the stock solution was
diluted with MES buffer. Colchicine, which was the other
positive control, and TBMS1 were dissolved in MES buf-
fer. Stock solutions of MTP were diluted on ice in cold
MES buffer to a ﬁnal concentration of 1.12 mg/ml. The
instrument was zeroed with this solution at 0C. Test
compounds (ﬁnal concentrations ranged from 2.5 to
40 lM) were then quickly mixed into the MTP solution.
The ﬁnal volume of the reaction mixtures was 250 ll.
Assembly was initiated by warming the solution from 0 to
37C and the polymerization process was monitored by
observing the variations in absorbance at 350 nm. After
16 min at 37C, the absorbance (A350) reached a plateau.
The temperature was held at 37C for more 20 min, and
then was rapidly lowered back to 0C. The assay was over
after incubation at 0C for 20 min. The absorbance read-
ings were taken every 3 min throughout the incubation
time. The temperature was held at 37C for 20 min and the
changes in absorbance was used to calculate the extent
of polymerization % ðÞ inhibition ¼ 1   A350sample=A350 ð ½
controlÞ 100% :
Sedimentation assay
The assay was performed as described by Mitsui-Saito
et al. [24]. In the assay, polymerized and non-polymerized
tubulin were separated by ultracentrifugation. The samples
(250 ll, 1.12 mg MTP/ml) were incubated in the presence
or absence of test compounds (paclitaxel and colchicine,
ﬁnal concentration at 2.5 lM; TBMS1, ﬁnal concentration
at 10 lM, respectively) for 20 min at 37C, and centri-
fuged at 105,000g at 37C for 1 h. The supernatant was
removed and the pellets were homogenized in 250 ll MES
buffer. Twenty microlitters homogenate was mixed with
sample-dissociating buffer and boiled for 4 min. These
samples were loaded on 10% (w/v) SDS-polyacrylamide
gel and electrophoresis was performed. The gel was stained
with Coomassie brilliant blue.
Immunoﬂuorescence microscopy
Microtubular cytoskeleton was observed according to the
methods of Isbrucker et al. [25]. CNE-2Z cells were seeded
on sterile glass coverslips in 6-well tissue culture plate at a
density of 2.5 9 10
5 cells/well and allowed to adhere and
grow for 24 h at 37C, 5% CO2. Attached cells were
treated with or without test compounds for 3 h. The culture
medium was removed and cells were rinsed with phos-
phate-buffered saline (PBS) prior to ﬁxation in 4% (v/v)
formaldehyde in PBS for 10 min at room temperature. The
ﬁxed cells were rinsed with PBS three times and perme-
abilized in 0.5% (v/v) Triton X-100 in PBS for 10 min and
rinsed four times again in PBS (every rinse needed
10 min). Cells were incubated with PBS containing 10%
(v/v) NCS for 10 min to block non-speciﬁc binding sites
before incubation for 45 min with the primary antibody
(mouse monoclonal anti-tubulin antibody, diluted at 1:400
in 10% w/v fat-free milk). Following three rinses in PBS
containing 1% (v/v) Triton X-100, cells were incubated
with the secondary antibody in the dark for 45 min (ﬂuo-
rescein isothiocyanate-conjugated goat anti-mouse IgG,
diluted at 1:150 in 10% w/v fat-free milk). All incubations
were carried out at room temperature with intermittent
shaking. Cells were then gently rinsed three times (10 min
each) in 2 ml of PBS containing 1% (v/v) Triton X-100 in
the dark. The coverslips were examined with Leica ﬂuo-
rescence microscope (DMIRB, Leica Microsystems,
Germany) equipped with appropriate ﬁlter sets. Photo-
graphs were taken with a Nikon camera, using Kodak Gold
400 ﬁlm, magniﬁcation 4009.
Analysis of soluble and polymerized tubulin
by immunoblotting
CNE-2Z cells were seeded at 1 9 10
5 per ml in tissue
culture ﬂasks. Paclitaxel (2.5 lM), colchicine (2.5 lM),
TBMS1 (10, 25 lM) or vehicle was added to ﬂasks con-
taining cells growing in log phase, respectively. Paclitaxel
was dissolved in DMSO and then further diluted to ﬁnal
concentration in culture medium. Colchicine and TBMS1
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123were dissolved in serum-free and antibiotic-free RPMI-
1640 medium to yield ﬁnal concentrations. Soluble (cyto-
solic) and polymerized (cytoskeletal) fractions of tubulin
were separated according to the methods of Kavallaris
et al. [26] with some modiﬁcations. Brieﬂy, after cells were
treated with the drugs for speciﬁed time intervals, they
were harvested and washed twice with cold PBS. Cells
were lysed at 37C for 10 min in the dark with 300 ll
hypotonic buffer (1 mM MgCl2, 2 mM EGTA, 0.5% v/v
Nonidet P-40, 5 mM e-amino-caproic acid, 0.01 nM ben-
zamidine, 20 mM Tris–HCl, pH 6.8, containing 20 lg/ml
aprotinin, 2 mM phenylmethylsulfonyl ﬂuoride, 1 mM
sodium orthovanadate and 100 lg/ml soybean trypsin
inhibitor). Soluble tubulin was collected in the supernatant
following centrifugation 18,000g for 10 min at room
temperature. The pellets were resuspended in 100 ll cold
hypotonic buffer and incubated on ice for 30 min. Insolu-
ble material was removed by centrifugation at 4C for
5 min at 200g. The resulting supernatant contained the
polymerized tubulin. Protein concentrations were deter-
minded using the Lowry’s method [22]. Immunoblotting
was performed as described above.
Effect of TBMS1 on vinblastine or colchicine binding
to tubulin [27–30]
Each 0.5 ml reaction contained 0.1 M MES (pH 7.0 with
NaOH in 1 M stock solution), 0.5 mM MgCl2,1 . 0m g / m lo f
tubulin, [
3H]Vinblastine or colchicine (1–5 lM) and the
indicated concentration of TBMS1 (0, 10, 20, 40 lM).
Tubulin was added last in every experiment and allowed to
incubate at 37C for 45 min (for vinblastine) or for 120 min
in the dark (for colchicine). Reaction mixtures were then
added to 1 ml microspin columns of Sephadex G-50
(superﬁne) and processed by centrifugal gel ﬁltration at room
temperature. The ﬁltrate was collected, and radioactivity was
determined by liquid scintillation counting, allowing calcu-
lation of a mole ratio of drug to tubulin for each experiment.
Controls determined that no radioactivity passed through the
column in the absence of tubulin. All lines were drawn by
linear regression, each regression line represents data from a
minimum of three individual experiments.
Results
Inhibition of CNE-2Z cell growth by TBMS1
Inhibition of cell growth was observed following treatment
of different doses of TBMS1 for 24, 48, 72 h. The inhib-
itory activity was dose- and time-dependent (Fig. 2), and
the estimated IC50 values after 24, 48, 72 h of TBMS1
treatment were 32.5, 20.7, 16.7 lM. All the experiments
were repeated at least three times.
Uptake of TBMS1 by CNE-2Z cells and the uptake
kinetics
HPLC analysis of TBMS1 uptake kinetics by CNE-2Z cells
displayed the initial markedly slow TBMS1 uptake, and
then gradually reaching an apparent maximum uptake near
18 h and a decrease in cellular uptake at 24 h suggesting
the cells dying and leaky (Fig. 3).
Identiﬁcation of MTP
The content of MTP was estimated to be 8 mg/ml. The
molecular weights of major components of MTP ranged
from 44.0 to 66.2 kDa. Immunoblotting with anti-tubulin
antibody conﬁrmed the identity of the major protein band as
tubulin (the a, b-tubulin monomers have very similar
molecularweights:about55 kDa).Analysisofdensitometry
of the bands suggested that the puriﬁcation procedure yiel-
ded a mixture of[90% heterodimeric a, b-tubulin (Fig. 4).
TBMS1-mediated inhibition of tubulin polymerization
The capacity of TBMS1 to inhibit MTP polymerization in
vitro was determined by monitoring turbidity changes with
temperature and time. The effect of TBMS1 on MTP
polymerization was compared with those of controls. The
results showed that 2.5 lM paclitaxel induced polymeri-
zation of MTP remarkably, and the polymer was stabilized
0 2 44 87 2
0.00
0.05
0.10
0.15
0.20
A
5
7
0
n
m
Time (h)
Control
5µM
10µM
20µM
30µM
40µM
50µM
Fig. 2 Dose- and time-response of TBMS1 on growth of CNE-2Z
cells. CNE-2Z cells were treated with various concentration of
TBMS1 for different time intervals. The cell proliferation was
determined by MTT assay. The values are expressed as mean ± SE
of three independent experiments
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123by paclitaxel even at 0C, but at the same concentration,
colchicine was effective at inhibiting polymerization of
MTP, and produced a 71.3% inhibition of MTP polymer-
ization (Fig. 5a). For TBMS1, it was effective at inhibition
of polymerization of MTP at all the concentrations tested,
and at concentrations lower than 10 lM, the effect was
dependent on concentration. Figure 5b showed the con-
centration-dependent inhibition of MTP polymerization by
TBMS1. Inhibition of MTP polymerization by TBMS1
could be distinguished at concentration as low as 5 lM,
and the maximum inhibition of MTP polymerization
occurred upon the addition of 40 lM TBMS1. Inhibition
rates (%) of TBMS1 at the concentrations of 5, 7.5, 10, 20,
40 lM were 10.7, 30.0, 44.7, 46.7 and 49.3%, respectively.
To further clarify the effect of TBMS1 on MTP poly-
merization, MTP polymerize in the presence or absence of
2.5 lM paclitaxel, 2.5 lM colchicine and 10 lM TBMS1
at 37C for 20 min, and the amounts of polymerized
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Fig. 3 Time course of TBMS1 uptake by CNE-2Z cells. CNE-2Z
cells were cultured with a ﬁnal concentration of TBMS1 of 30 lM.
Samples were taken at speciﬁed time intervals and prepared as
described in ‘‘Materials and methods’’. The methanolic extracts were
used for the assays of TBMS1 concentrations by HPLC using
Hypersil ODS column (5 lm 4.0 9 250 mm). HPLC analysis of time
course of TBMS1 uptake by CNE-2Z cells displayed the initial
markedly slow TBMS1 uptake, and then gradually reaching an
apparent maximum uptake near 18 h and a decrease in cellular uptake
at 24 h suggesting the cells dying and leaky
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Fig. 4 Tubulin purity assessment: analysis by SDS-PAGE and
immunoblotting. a A 10% gel stained with Coomassie brilliant blue.
b A membrance probed with an anti-tubulin antibody. M marker; lane
a:1 6lg sample of rude microtubulin protein preparation; lane b:
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microtubulin protein. Analysis of densitometry of the bands suggested
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Fig. 5 Effect of TBMS1 on the polymerization of MTP in vitro by
turbidity measurement. Reaction mixtures containing MES buffer and
1.12 mg/ml MTP were held at 0C; at time zero, test compounds were
added and mixed into the reaction mixture, and then the temperature
was shifted to 37C. The turbidity of the solution was measured at an
absorbance of 350 nm every 3 min. At the time indicated by the
arrow, the temperature of the reaction mixture was shifted at 0C. a
MTP was incubated in the absence (-) or presence of 2.5 lM
paclitaxel (ﬁlled triangle), 2.5 lM colchicine (open triangle) and
10 lM TBMS1 (9); b MTP was incubated in the absence (-)o r
presence of TBMS1 at concentrations of 5 lM( ﬁlled circle), 7.5 lM
(open square), 10 lM( 9), 20 lM( ﬁlled diamond) and 40 lM (+)
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123fractions were visualized by SDS-PAGE followed by
staining with Coomassie brilliant blue after separation
using an ultracentrifuge. Obviously, the amount of poly-
merized tubulin induced by TBMS1 was more than that
induced by colchicine, but less than that of the control, and
much less than that induced by paclitaxel, and the results of
analysis of densitometry of the bands expressed as percent
of the control value deﬁned as 100% were given below:
TBMS1 (10 lM), 34.6%; colchicine (2.5 lM), 3.2%;
paclitaxel (2.5 lM), 196. 4% (Fig. 6). These results sug-
gested that TBMS1 had direct inhibitory effect on
polymerization of MTP in vitro, but the effect was rela-
tively weak.
Interaction of TBMS1 with cellular microtubules
The interaction of TBMS1 with cellular microtubules was
examined by immunoﬂuorescence techniques in CNE-2Z
cells. Untreated cells exhibited well-deﬁned, cytoplasmic
microtubule arrays radiating from the center to the cell
periphery, and the control image demonstrated several
dividing cells with normal spindles (Fig. 7a). Paclitaxel
increased microtubule polymerization by promoting
nucleation and elongation of the polymers and rearrange-
ment of microtubules into bundle formations, stabilizing
the microtubule lattice and bundling microtubules. Cellular
microtubules of CNE-2Z cells treated with paclitaxel were
abnormally assembled either in abundant arrays of disor-
ganized microtubules in parallel ‘‘bundles’’ or in mitotic
asters, and the microtubule bundles were predominant
(Fig. 7b). Colchicine resulted in depolymerization of cel-
lular microtubules, caused CNE-2Z cells to round up and
the tubulin took on an amorphous appearance (Fig. 7c).
The interaction of TBMS1 with tubulin within CNE-2Z
cells was similar to that of colchicine. Treatment with
TBMS1 (25 lM, 3 h) induced a marked effect on the
microtubular network. Under the experimental conditions,
cells rounded, and were devoid of properly formed
Fig. 7 Immunoﬂuorescence
images of CNE-2Z cells treated
with TBMS1. Cells were
cultured for 24 h and then
incubated without (a) or with
2.5 lM paclitaxel (b), 2.5 lM
colchicine (c) and 25 lM
TBMS1 (d) for 3 h. The ﬁxed
cells were stained with the anti-
tubulin primary antibody and
the ﬂuorescein 5-
isothiocyanate-conjugated
secondary antibody as described
in ‘‘Materials and methods’’.
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Fig. 6 Effect of TBMS1 on the polymerization of MTP by a
sedimentation assay. MTP was incubated with or without test
compounds at 37C for 20 min. The reaction mixture was ultracen-
trifuged and the pellets were separated by SDS-PAGE. The gel was
stained with Coomassie brilliant blue. Tubulin (approximately
55 kDa) in lane 4 (10 lM TBMS1) is more than that in lane 3
(2.5 lM colchicine), but less than that in lane 1 (untreated control).
Paclitaxel (2.5 lM) induced the most polymerization tubulin (lane 2).
M marker. The results of analysis of densitometry of the bands
expressed as percent of the control value deﬁned as 100% were given
below: TBMS1 (10 lM), 34.6%; colchicine (2.5 lM), 3.2%; paclit-
axel (2.5 lM), 196.4%
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123microtubules, and the cytoplasm was full of tubulin ﬂuo-
rescence (Fig. 7d). In addition, cells exposed to colchicine
and TBMS1 were detached easier from the adherent cov-
erslips than those untreated or treated with paclitaxel.
The effect of TBMS1 on tubulin was compared with
those of paclitaxle and colchicine. Soluble and polymer-
ized pools of tubulin were separated from cell lysates and
the relative proportions were determined by Western
blotting. The cells treated with paclitaxel greatly increased
the amounts of polymerized tubulin compared to the con-
trol cells, whereas colchicine and TBMS1 increased the
amounts of soluble tubulin, and 25 lM TBMS1 induced
more soluble tubulin than 10 lM TBMS1. Furthermore, a
shift in tubulin from a particulate to soluble form was
observed after cells were treated with 25 lM TBMS1 for 1,
6, 12, or 24 h, and the results suggested that at a certain
concentration of TBMS1, soluble fractions of tubulin
increased in a time-dependent manner (Fig. 8).
Effect of TBMS1 on vinblastine and colchicine binding
to tubulin
Competitive binding assays using vinblastine and colci-
chine were employed to determine if TBMS1 occupied
which one of these two known sites. The results obtained
from this study showed that TBMS1 did not inhibit the
binding of vinblastine to tubulin (data not shown). Detailed
studies were performed to determine whether TBMS1 was a
competitive inhibitor of colchicine binding, thus interacting
at the colchicine site. In the Hanes format, these data yiel-
ded parallel curves at different TBMS1 concentrations
(Fig. 9a), consistent with competitive inhibition (with non-
competitive inhibition the curves intercept on the abscissa)
[30]. Lineweaver–Burk analysis yielded lines that inter-
cepted at positive abscissa, also indicating that this
inhibition was competitive (Fig. 9b) [28]. Replotted in the
Dixon format [31], the data yield an apparent Ki value of
57.9 ± 5.0 lM (average ± SD) for TBMS1.
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Fig. 8 Effect of TBMS1 on tubulin in CNE-2Z cells by immuno-
blotting. Total cellular protein (30 lg/lane) was separated on 10%
SDS-PAGE, electrotransferred to nitrocellulose, and immunodetected
with an anti-tubulin antibody. Lanes 1, 6: control, 24 h; lane 2:
2.5 lM paclitaxel, 24 h; lane 3: 2.5 lM colchicine, 24 h; lanes 4, 5:
10, 25 lM TBMS1, 24 h; lanes 7–10:2 5lM TBMS1, 1, 6, 12, 24 h.
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Fig. 9 Effect of TBMS1 on colchicine binding to tubulin. Each
0.5 ml reaction mixture contained 0.1 M MES (pH 7.0 with NaOH in
1 M stock solution), 0.5 mM MgCl2, 1.0 mg/ml of tubulin, [
3H]col-
chicine(1–5 lM) and the indicated concentration of TBMS1. Tubulin
was added last in every experiment and allowed to incubate at 37C
for 120 min in the dark. Reaction mixtures were then added to 1 ml
microspin columns of Sephadex G-50 (superﬁne) and processed by
centrifugal gel ﬁltration at room temperature. The ﬁltrate was
collected, and radioactivity was determined by liquid scintillation
counting, allowing calculation of a mole ratio of drug to tubulin for
each experiment. Controls determined that no radioactivity passed
through the column in the absence of tubulin. For the experiment
presented above the following concentrations of tubeimoside I were
used: (open diamond) none; (ﬁlled circle)1 0 lM; (open square)
20 lM; (ﬁlled triangle)4 0 lM. All lines were drawn by linear
regression, and R
2 values for all ﬁts were above 0.97. Each regression
line represents data from a minimum of three individual experiments
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Of particular interest has been the search for the cellular
and molecular mechanisms underlying the anti-tumor
effects of TBMS1. In the present study, we demonstrated
inhibitory effect of TBMS1 on polymerization of MTP and
uptake by tumor cells in vitro, and revealed that TBMS1
resulted in depolymerization of cellular microtubules and
increase of the amount of soluble tubulin in CNE-2Z cells,
and that TBMS1 was a competitive inhibitor of colchicine
binding. These ﬁndings suggest that TBMS1 is an anti-
microtubule agent, and its binding site of tubulin is the
colchicine binding site of tubulin. TBMS1 as a natural
product anti-microtubule agent adds to the growing list of
agents with this mechanism of action, but the impression
that we obtain from this study is that TBMS1 is a weak
tubulin inhibitor, although any new natural product that has
this mechanism of action has inherent interest.
TBMS1 has a core structure that is reminiscent of a
steroid molecule. TBMS1 shares obvious structural
homology with 2-methoxyestradiol and analogues, which
cause microtubule depolymerization, and inhibition of the
assembly of puriﬁed tubulin [32], and with taccalonolides,
plant-derived steroid-like molecules that induce tubulin
assembly and cause an increased density of celluar micro-
tubules in interphase cells and the formation of thick
bundles of microtubules similar to effects of Taxol [33]. In
addition, bicyclic peptides celogentins A–C isolated from
the seeds of Celosia argentea (Amaranthaceae), inhibit the
polymerization of tubulin [34]. Obviously, it is of signiﬁ-
cance to study the relationship of structure-activity of
mentioned above compounds, including TBMS1.
The atypical tubulin turbidity proﬁle—increasing inhi-
bition of tubulin polymerization at low concentrations, with
maximal and about 50% inhibition occurring with con-
centrations 10 lM and higher—was observed with
TBMS1. Such patterns have been reported by other authors
with the explanation suggested of limited aqueous solu-
bility [35]. Due to hydrophobic nature of the pockets of the
binding sites of paclitaxel, vinca alkaloid and colchicine, it
is quite surprised that TBMS1 as a hydrophilic water-
soluble compound is able to interact with tubulin. It
seemed as if we could not think of the right explanation.
Perhaps TBMS1 is a partial agonist.
Anti-microtubule agents are tubulin binding compounds.
Tubulin binding molecules interfere with the dynamic
instability of microtubules and thereby arrest mitotic cells
in the M-phase of the cell division cycle, ﬁnally leading to
apoptotic cell death. Tubulin binding molecules from nat-
ure include colchicine, the vinca alkaloids vinblastine and
vincristine, rhizoxin, maytansine, combretastatin A4, epo-
thilone, paclitaxel, and dolastatin 10 [36] and dolastatin 15
[37]. To our current knowledge, natural compounds bind to
distinct sites within b-tubulin and by destability or stabil-
ization of microtubules, cause mitotic catastrophe [23].
Palitaxel and Taxotere are stabilizing tubulin inhibitors
used clinically for the treatment of breast, ovarian, and
non-small cell lung cancer, whereas vincristine and vin-
blastine are destabilizing tubulin inhibitors indicated for
acute lymphatic leukemia, Hodgkin disease, and advanced
breast cancer [38]. The tubulin inhibitors used for human
cancer therapy have severe drawbacks, i.e., dose-limiting
toxicity (especially neurotoxicity), marginal oral bioavail-
ability and poor solubility, complex synthesis and isolation
procedures with low yield, and most importantly, the
development of drug resistance, which is a common phe-
nomenon. Although TBMS1 is a natural compound with
complex structure, its isolation procedures are not too
complex, and the yields (1.85%) are relatively high.
Moreover, it is water-soluble, and has high oral bioavail-
ability with acceptable therapeutic index. Therefore,
TBMS1 is a highly attractive candidate of anti-tumor
agent.
In summary, the anti-microtubule activity of TBMS1
probably results from its binding at the colchicine site of
tubulin. Analysis of TBMS1 uptake kinetics by CNE-2Z
cells displayed the initial markedly slow TBMS1 uptake
and then gradually reaching an apparent maximum uptake
near 18 h. TBMS1 inhibits tubulin polymerization at
higher concentrations. The ﬁndings may be of beneﬁt to
elucidating the cellular and molecular mechanisms under-
lying the anti-tumor effects of TBMS1.
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